In cHL patients, RP6530 showed objective responses in a phase I trial that were associated with a significant inhibition of circulating MDSCs and a reduction in serum levels of the poor prognosis factor CCL17/TARC [36]. This evidence concerns the gene CCL17 and classic Hodgkin lymphoma.